Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Cost of Revenue (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Cost of Revenue for 3 consecutive years, with $28.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 22.51% to $28.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $173.2 million, a 85.72% increase, with the full-year FY2025 number at $173.2 million, up 85.72% from a year prior.
  • Cost of Revenue was $28.3 million for Q4 2025 at Iovance Biotherapeutics, down from $38.5 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $56.7 million in Q2 2025 to a low of -$5.4 million in Q4 2023.
  • A 3-year average of $26.5 million and a median of $29.8 million in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 626.22% in 2024, then grew 22.08% in 2025.
  • Iovance Biotherapeutics' Cost of Revenue stood at -$5.4 million in 2023, then skyrocketed by 531.23% to $23.1 million in 2024, then grew by 22.51% to $28.3 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Cost of Revenue are $28.3 million (Q4 2025), $38.5 million (Q3 2025), and $56.7 million (Q2 2025).